Side-by-side · Research reference
HGH Fragment 176-191vsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED28/59 cited
BFDA-ApprovedFlagship14/45 cited
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
HGH Fragment 176-191
Liraglutide
Primary target
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
N/A — does not interact with GH/IGF-1 axis
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Antibody development
Not reported in available studies
—
02Dosage Protocols
Parameter
HGH Fragment 176-191
Liraglutide
Animal dose (IP)
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
—
Human equivalent dose
Not established — no published human RCTs
—
Frequency
Once daily (animal models)
Once daily, same time each day
Evidence basis
Animal studies only
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Detection window
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
—
Oral bioavailability
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
—
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Reconstitution
—
Pre-filled commercial pen (no reconstitution)
Timing
—
Any time of day; consistent
03Metabolic / Fat Loss Evidence
Parameter
HGH Fragment 176-191
Liraglutide
Weight gain reduction
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
—
Body fat reduction
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
—
Lipolytic activity
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
—
Insulin sensitivity
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
—
IGF-1 impact
No elevation — fragment does not activate GH/IGF-1 axis
—
Beta-3 AR dependency
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
—
Human evidence
None published — pre-clinical only
—
04Side Effects & Safety
Parameter
HGH Fragment 176-191
Liraglutide
Human safety data
Not available — no published human trials
—
Metabolic profile
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
—
GI symptoms
—
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
HGH Fragment 176-191
Liraglutide
1. Route
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
Commercial pre-filled pen, no reconstitution required.
2. Frequency
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Duration
Animal protocols: 14–19 days. Human duration not established — no published trials.
Once daily, same time each day. Take with or without food.
4. Storage
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Detection
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
Pen-supplied 32G needle.